Stock Track | Corvus Pharmaceuticals Plummets 10.61% Intraday on Dilution Fears from Expanded $200 Million ATM Facility

Stock Track03-19 03:18

Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.

The biopharmaceutical company recently filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, providing flexibility to issue common and preferred stock, debt, warrants and units. This expanded financing capacity comes as Corvus continues to run multiple clinical trials for its lead candidate soquelitinib across dermatology, pulmonary medicine, rheumatology and oncology indications.

Investors appear concerned about potential "value destructive dilution" as the company, which reported a US$15.28 million net loss for full year 2025 and has no product revenue, may need to raise additional capital through equity issuance to fund its ongoing clinical programs. The expanded ATM facility increases the risk of share dilution for existing shareholders, particularly if the company leans heavily on this financing option ahead of key clinical readouts for soquelitinib.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118422614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 03:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118422614","market":"hk","top_or_hot":-1,"title":"Stock Track | Corvus Pharmaceuticals Plummets 10.61% Intraday on Dilution Fears from Expanded $200 Million ATM Facility","media":"Stock Track","content":"<p>Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.</p><p>The biopharmaceutical company recently filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, providing flexibility to issue common and preferred stock, debt, warrants and units. This expanded financing capacity comes as Corvus continues to run multiple clinical trials for its lead candidate soquelitinib across dermatology, pulmonary medicine, rheumatology and oncology indications.</p><p>Investors appear concerned about potential \"value destructive dilution\" as the company, which reported a US$15.28 million net loss for full year 2025 and has no product revenue, may need to raise additional capital through equity issuance to fund its ongoing clinical programs. The expanded ATM facility increases the risk of share dilution for existing shareholders, particularly if the company leans heavily on this financing option ahead of key clinical readouts for soquelitinib.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corvus Pharmaceuticals Plummets 10.61% Intraday on Dilution Fears from Expanded $200 Million ATM Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corvus Pharmaceuticals Plummets 10.61% Intraday on Dilution Fears from Expanded $200 Million ATM Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-19 03:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.</p><p>The biopharmaceutical company recently filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, providing flexibility to issue common and preferred stock, debt, warrants and units. This expanded financing capacity comes as Corvus continues to run multiple clinical trials for its lead candidate soquelitinib across dermatology, pulmonary medicine, rheumatology and oncology indications.</p><p>Investors appear concerned about potential \"value destructive dilution\" as the company, which reported a US$15.28 million net loss for full year 2025 and has no product revenue, may need to raise additional capital through equity issuance to fund its ongoing clinical programs. The expanded ATM facility increases the risk of share dilution for existing shareholders, particularly if the company leans heavily on this financing option ahead of key clinical readouts for soquelitinib.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1118422614","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118422614","pubTimestamp":1773861517,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"个股追踪|Corvus Pharmaceuticals盘中暴跌10.61%，因担心扩建2亿美元ATM设施造成稀释","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"Corvus Pharmaceuticals' stock plummeted 10.61% during intraday trading on Wednesday, as investors reacted negatively to the company's expanded financing capacity that raises dilution concerns.The biopharmaceutical company recently filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, providing flexibility to issue common and preferred stock, debt, warrants and units. This expanded financing capacity comes as Corvus continues to run multiple clinical trials for its lead candidate soquelitinib across dermatology, pulmonary medicine, rheumatology and oncology indications.Investors appear concerned about potential \"value destructive dilution\" as the company, which reported a US$15.28 million net loss for full year 2025 and has no product revenue, may need to raise additional capital through equity issuance to fund its ongoing clinical programs. The expanded ATM facility increases the risk of share dilution for existing shareholders, particularly if the company leans heavily on this financing option ahead of key clinical readouts for soquelitinib.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118422614","isCrawlerRequest":true}